



70. (Previously presented) The method of claim 69, wherein the antigen-presenting cell is selected from the group consisting of B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts and oligodendrocytes.

71. (Previously presented) The method of claim 69, wherein the antigen-presenting cell is a B lymphocyte.

72. (Previously presented) The method of claim 71, wherein the B lymphocyte is an activated B lymphocyte.

73. (Previously presented) The method of claim 72, wherein the activated B lymphocyte is a splenic activated B lymphocyte.

74. (Previously presented) The method of claim 69, wherein the antigen-presenting cell is a lymphoid cell.

75. (Previously presented) The method of claim 69, wherein the antigen-presenting cell is a peripheral blood lymphocyte.

76. (Previously presented) The method of claim 69, wherein the antigen-presenting cell is a bone marrow lymphocyte.

77. (Previously presented) The method of claim 69, wherein the antigen-presenting cell is a Langerhans cell.

78. (Previously presented) The method of claim 69, wherein the antigen-presenting cell is a dendritic cell.

79. (Previously presented) The method of claim 69, wherein the anti-gp39 antibody is an anti-human anti-gp39 antibody.

80. (Previously presented) The method of claim 79, wherein the anti-human anti-gp39 antibody is humanized.

81. (Previously presented) The method of claim 79, wherein the anti-human anti-gp39 antibody is a chimeric anti-human anti-gp39 antibody containing human constant regions.